Commercial Drug Patient Journey Experience
Named therapies, growth metrics, and program roles.
Crysvita (burosumab)
Context
XLH and TIO; post-launch programs and longitudinal observation.
Evidence
$87.3M → $410.0M (2019–2024).
Role
- BEYONDXLH Phase IV Lead
- Yale School of Medicine partner
- XLH Network partner
Crysvita · XLH · TIO · BEYONDXLH
Dojolvi (triheptanoin)
Context
LC-FAOD; diet-managed metabolic care with specialist oversight.
Evidence
$6.4M → $88.0M (2020–2024).
Role
- Innovation Lab Founder and Leader (~54-person team)
- Rarify Platform Lead
- Global pivotal Phase III support for Dojolvi
Dojolvi · LC-FAOD · Rarify · Phase III